Katharina Zeschky

The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice

C. Bode, C. von zur Muhlen, A. Zirlik, 2011, Arteriosclerosis, thrombosis, and vascular biology.

Binding of CD40L to Mac-1's I-Domain Involves the EQLKKSKTL Motif and Mediates Leukocyte Recruitment and Atherosclerosis—But Does Not Affect Immunity and Thrombosis in Mice

P. Libby, C. Bode, K. Peter, 2011, Circulation research.

Cannabinoid Receptor 2 Signaling Does Not Modulate Atherogenesis in Mice

C. Bode, C. von Zur Mühlen, M. Moser, 2010, PloS one.

Deficient Mice - Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates

C. Bode, A. Zirlik, P. Stachon, 2011 .

Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice

K. Peter, C. von zur Muhlen, A. Zirlik, 2014, Thrombosis and Haemostasis.